SLx-2119(KD-025,Belumosudil )

Cas No.:	911417-87-3
Chemical Name:	2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide
Synonyms:	SLx2119(KD025)，SLx 2119(KD 025)，SLx2119，KD025
SMILES:	O=C(C([H])([H])OC1=C([H])C([H])=C([H])C(C2=NC3=C([H])C([H])=C([H])C([H])=C3C(N([H])C(C([H])=C4[H])=C([H])C5=C4N([H])N=C5[H])=N2)=C1[H])N([H])C(C([H])([H])[H])([H])C([H])([H])[H]
Formula:	C26H24N6O2
M.Wt:	452.51
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	SLx-2119 is a selective inhibitor of ROCK2 with an IC50 of 105 nM.
In Vivo:	KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males[2].
In Vitro:	SLx-2119 (40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays[1].